Cited by 1,930Erythropoietin and Anemia TreatmentDialysis and Renal Disease ManagementBlood transfusion and management

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Open access

Besarab, Anatole, Bolton, W. Kline, Browne, Jeffrey K., Egrie, Joan C., Nissenson, Allen R., Okamoto, Douglas M., Schwab, Steve J., Goodkin, David A.·1998·New England Journal of Medicine

DOI 10.1056/nejm199808273390903

Open this paper in CoChat — free account Open PDF

Abstract

BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199808273390903

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease: Results of a Phase III Multicenter Clinical Trial
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citation
Impact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
(1990) · BMJ · doi:10.1136/bmj.300.6724.573 · Cited by 427
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401

Show all 28 references

Research works printed but not linked: 8

Pascual J, 1991, Clin Nephrol, 35, 280
Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
Collins A, 1994, J Am Soc Nephrol, 5, 439
Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
Barany P, 1996, J Am Soc Nephrol, 7, 1472
Benz RL, 1996, J Am Soc Nephrol, 7, 1473
Hoen B, 1995, Nephrol Dial Transplant, 10, 377
Collins A, 1997, J Am Soc Nephrol, 8, 190A

Sorted by citations

Items 701–800 of 1,000

Anemia Management in the Cardiorenal Patient: A Nephrological Perspective
Marqués, M., Portolés, J. M., Marcos, M. C., Gorriz, J. L., Núñez, J. E., & Cases, A. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037363 · Cited by 21
The elderly patients on hemodialysis.
Anand, S., Tamura, M. K., & Chertow, G. M. (2010) · PubMed · Cited by 21
Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm
Skali, H., Lin, J., Pfeffer, M. A., Chen, C.-Y., Cooper, M. E., McMurray, J. J. V., Nissenson, A. R., Remuzzi, G., Rossert, J., Parfrey, P. S., et al. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.08.043 · Cited by 21
Self-citation
Anemia and the Heart in Chronic Kidney Disease
Zalunardo, N., & Levin, A. (2006) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2006.05.005 · Cited by 21
Hematologic Aspects of Kidney Disease
Brugnara, C., & Eckardt, K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10056-9 · Cited by 21
The mortality risk associated with higher hemoglobin: is the therapy to blame?
Rosner, M. H., & Bolton, W. K. (2008) · Kidney International · doi:10.1038/ki.2008.263 · Cited by 21
Self-citation
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors
Mann, J. F. E. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84178-8 · Cited by 21
Erythropoietin in cardiac disease: New features of an old drug
Ruifrok, W.-P. T., de Boer, R. A., Westenbrink, B. D., van Veldhuisen, D. J., & van Gilst, W. H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.01.054 · Cited by 21
Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population
Arneson, T. J., Zaun, D. A., Peng, Y., Solid, C. A., Dunning, S. C., & Gilbertson, D. T. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp018 · Cited by 21
Anemia in Chronic Kidney Disease: New Advances
Patel, T. V., & Singh, A. K. (2010) · Heart Failure Clinics · doi:10.1016/j.hfc.2010.02.001 · Cited by 21
Are all erythropoiesis-stimulating agents created equal?
Locatelli, F., Vecchio, L. D., Nicola, L. D., & Minutolo, R. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa034 · Cited by 21
Negative outcome studies in end-stage renal disease: how dark are the storm clouds?
Covic, A. C., Gusbeth–Tatomir, P., & Goldsmith, D. J. A. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm706 · Cited by 21
Traditional and Novel Approaches to Management of Heart Failure: Successes and Failures
Anand, I. S., & Florea, V. G. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2008.01.001 · Cited by 21
NORMALIZATION OF HEMATOCRIT IN HEMODIALYSIS PATIENTS DOES NOT AFFECT SILENT ISCHEMIA
Conlon, P. J., Conlon, P. J., Kovalik, E. C., Schumm, D., Minda, S. A., & Schwab, S. J. (2000) · Renal Failure · doi:10.1081/jdi-100100864 · Cited by 21
Self-citation
Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol
Strippoli, G. F. (2010) · Trials · doi:10.1186/1745-6215-11-70 · Cited by 21
Intravenous iron supplementation in the anaemia of renal and cardiac failure—a double-edged sword?
Slotki, I. N. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1102 · Cited by 21
Prevalence and Prognostic Significance of Anemia in Patients With Congestive Heart Failure Treated With Standard vs High Doses of Enalapril
Terrovitis, J. V., ANASTASIOU‐NANA, M. I., Alexopoulos, G. P., Tsolakis, E. J., Margari, Z. J., Drakos, S. G., Tsagalou, E. P., Papazoglou, P., Efentakis, S., & Nanas, J. N. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2005.09.019 · Cited by 21
Imputing Physical Health Status Scores Missing Owing to Mortality
Revicki, D. A., Gold, K. F., Buckman, D. W., Chan, K. S., Kallich, J. D., & Woolley, J. M. (2001) · Medical Care · doi:10.1097/00005650-200101000-00008 · Cited by 21
Clinical Evaluation of a New High Efficiency Hemodialyzer: Polysynthane™
Clark, W. R., & Shinaberger, J. H. (2000) · ASAIO Journal · doi:10.1097/00002480-200005000-00009 · Cited by 21
Target Hemoglobin Level for EPO Therapy in CKD
Parfrey, P. S. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.11.001 · Cited by 21
Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease
Strippoli, G., Manno, C., Fp, S., & Craig, J. C. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003967 · Cited by 21
Changes in Hemoglobin Level Distribution in US Dialysis Patients From June 2006 to November 2008
Spiegel, D. M., Khan, I., Krishnan, M., & Mayne, T. J. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.09.024 · Cited by 20
The safety and efficacy of peginesatide in patients with CKD
Eckardt, K. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.42 · Cited by 20
Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients
Hahn, D., Cody, J. D., & Hodson, E. M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003895.pub3 · Cited by 20
The effect of erythropoietin on bone
Rölfing, J. D. (2014) · Acta Orthopaedica · doi:10.3109/17453674.2013.869716 · Cited by 20
Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats
Kiss, K., Csonka, C., Pálóczi, J., Pipis, J., Görbe, A., Kocsis, G. F., Murlasits, Z., Sárközy, M., Szűcs, G., Holmes, C. P., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.013 · Cited by 20
Hypoxia-Inducible Factor Stabilization as an Emerging Therapy for CKD-Related Anemia: Report From a Scientific Workshop Sponsored by the National Kidney Foundation
Wish, J. B., Eckardt, K., Kovesdy, C. P., Fishbane, S. N., Spinowitz, B., & Berns, J. S. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.06.019 · Cited by 20
THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Applying Multiple Interventions in Chronic Kidney Disease
Barrett, B. J. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16032.x · Cited by 20
Relation between level or change of hemoglobin and generic and disease-specific quality of life measures in hemodialysis
Plantinga, L., Fink, N. E., Jaar, B. G., Huang, I., Wu, A. W., Meyer, K. B., & Powe, N. R. (2007) · Quality of Life Research · doi:10.1007/s11136-007-9176-6 · Cited by 20
Clinical Practice Guidelines for evidence-based use of erythropoietic-stimulating agents
MOIST, L. M., Foley, R. N., Barrett, B. J., Madore, F., White, C. T., Klarenbach, S. W., Culleton, B. F., Tonelli, M. A., & Manns, B. (2008) · Kidney International · doi:10.1038/ki.2008.270 · Cited by 20
Biological functions and therapeutic use of erythropoiesis‐stimulating agents: perplexities and perspectives
Merchionne, F., & Dammacco, F. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07702.x · Cited by 20
Individualizing Decision-Making—Resurrecting the Doctor-Patient Relationship in the Anemia Debate
Agarwal, R. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02830310 · Cited by 20
Trends in Patient and Technique Survival in Peritoneal Dialysis and Strategies: How Are We Doing and How Can We Do Better?
Blake, P. G. (2000) · Advances in Renal Replacement Therapy · doi:10.1053/jarr.2000.16531 · Cited by 20
Managing anemia in patients with chronic heart failure: what do we know?
Besarab, A. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4619 · Cited by 20
Self-citation
Therapy Insight: management of cardiovascular disease in the renal transplant recipient
Rigatto, C., & Parfrey, P. S. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0253 · Cited by 20
Anemia, Renal Transplantation, and the Anemia Paradox
Rigatto, C. (2006) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2006.05.007 · Cited by 20
Disease Progression and the Application of Evidence-Based Treatment Guidelines Diagnose It Early: A Case for Screening and Appropriate Management
Manley, H. J. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.9-d.6 · Cited by 20
Vitamin D in Patients with Chronic Kidney Disease: Nothing New under the Sun
Tonelli, M. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-12-200712180-00009 · Cited by 20
Trends in anemia management in US hemodialysis patients 2004–2010
The DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators, Miskulin, D. C., Zhou, J., Tangri, N., Bandeen‐Roche, K., Cook, C., Ephraim, P. L., Crews, D. C., Scialla, J. J., Sozio, S. M., et al. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-264 · Cited by 19
Erythropoiesis-Stimulating Agents: Dose and Mortality Risk
Bellinghieri, G., Condemi, C. G., Saitta, S., Trifirò, G., Gangemi, S., Savica, V., Buemi, M., & Santoro, D. (2014) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2014.10.012 · Cited by 19
Long‐term prognostic impact of the use of erythropoietic‐stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib
Santos, F. P. D. S., Alvarado, Y., Kantarjian, H. M., Verma, D., O'Brien, S. M., Mattiuzzi, G. N., Ravandi, F., Borthakur, G. M., & Cortes, J. E. (2010) · Cancer · doi:10.1002/cncr.25533 · Cited by 19
Pharmacologic Management of Chronic Reno-Cardiac Syndrome
Hawwa, N., Schreiber, M. J., & Tang, W. H. W. (2012) · Current Heart Failure Reports · doi:10.1007/s11897-012-0122-8 · Cited by 19
Whole‐blood viscosity increases significantly in small arteries and capillaries in hemodiafiltration. Does acute hemorheological change trigger cardiovascular risk events in hemodialysis patient?
Canaud, B., Rodriguez, A., Chénine, L., Morena-Carrere, M., Jaussent, I., Leray‐Moragues, H., Picard, A., & Cristol, J. (2010) · Hemodialysis International · doi:10.1111/j.1542-4758.2010.00496.x · Cited by 19
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial
Singh, A. K., Blackorby, A., Čižman, B., Carroll, K., Cobitz, A. R., Davies, R., Jha, V., Johansen, K. L., Lópes, R. D., Kler, L., et al. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab065 · Cited by 19
Anaemia Management in Chronic Kidney Disease
Macdougall, I. C. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5547-8_50 · Cited by 19
Mechanisms and Treatment of Anemia in Chronic Heart Failure
Katz, S. D. (2004) · Congestive Heart Failure · doi:10.1111/j.1527-5299.2004.03298.x · Cited by 19
Erythropoietin update 2011
Kowalczyk, M., Banach, M., Mikhailidis, D. P., & Rysz, J. (2011) · Medical Science Monitor · doi:10.12659/msm.882037 · Cited by 19
Iron replacement therapy
Nielsen, O. H., Coskun, M., & Weiß, G. (2016) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000247 · Cited by 19
Buttonhole versus Stepladder Cannulation for Home Hemodialysis
Huang, S. S., MacRae, J. M., Ross, D., Imtiaz, R., Hollingsworth, B., NESRALLAH, G. E., Copland, M. A., McFarlane, P. A., Chan, C. T., & Zimmerman, D. L. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08310718 · Cited by 19
Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure
Maxwell, A. P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00474.x · Cited by 19
Bundled Payment Models for Actinic Keratosis Management
Kirby, J. S., Delikat, A., LESLIE, D. L., & Miller, J. J. (2016) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.0502 · Cited by 18
Low rather than high mean corpuscular volume is associated with mortality in Japanese patients under hemodialysis
Honda, H., Kimachi, M., Kurita, N., Joki, N., & Nangaku, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-72765-2 · Cited by 18
Coronary Artery Disease in Chronic Kidney Disease: Need for a Heart–Kidney Team-Based Approach
Shroff, G. R., Carlson, M. D., & Mathew, R. O. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.30 · Cited by 18
Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis
Tian, L., Wang, M., Liu, M., Pang, Y., Zhao, J., Zheng, B., Wang, Y., & Zhao, W. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2313864 · Cited by 18
Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat
Reis, F., Teixeira, M., Rodrigues‐Santos, P., Garrido, P., Costa, E. M., Parada, B., Sereno, J., Alves, R., Belo, L., Teixeira, F. J., et al. (2012) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.92743 · Cited by 18
Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study
Toida, T., Iwakiri, T., Sato, Y., Komatsu, H., Kitamura, K., & Fujimoto, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169117 · Cited by 18
Individualized anemia management in a dialysis facility – long-term utility as a single-center quality improvement experience
Gawęda, A. E., Jacobs, A. A., Aronoff, G. R., & Brier, M. E. (2018) · Clinical Nephrology · doi:10.5414/cn109499 · Cited by 18
Erythropoietin suppresses epithelial to mesenchymal transition and intercepts Smad signal transduction through a MEK-dependent mechanism in pig kidney (LLC-PK1) cell lines
Chen, C., Chou, K.-J., Lee, P., Chen, Y.-S., Chang, T.-Y., Hsu, C., Huang, W.-C., Chung, H., & Fang, H.-C. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.022 · Cited by 18
Past, Present, and Future of Chronic Kidney Disease Anemia Management in the United States
Wish, J. B. (2009) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2008.12.005 · Cited by 18
Epoetin-induced pure red cell aplasia: diagnosis and treatment
Macdougall, I. C. (2007) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e3282f0c4bf · Cited by 18
The Effect of Altitude Change on Anemia Treatment Response in Hemodialysis Patients
Brookhart, M. A., Bradbury, B. D., Avorn, J., Schneeweiß, S., & Winkelmayer, W. C. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwq423 · Cited by 18
Misconceptions, Challenges, Uncertainty, and Progress in Guideline Recommendations
Kunz, R., Djulbegović, B., Schünemann, H. J., Stanulla, M., Muti, P., & Guyatt, G. H. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2008.04.005 · Cited by 18
Goal-directed antihypertensive therapy: Lower may not always be better
Filippone, E. J., Foy, A., & Newman, E. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10101 · Cited by 18
Reviews: Should the Target Hemoglobin for Patients with Chronic Kidney Disease Treated with Erythropoietic Replacement Therapy be Changed?
Berns, J. S. (2005) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2005.18105.x · Cited by 18
Re-evaluating the Transfusion Trigger: How Low Is Safe?
Crosby, E. T. (2002) · American Journal of Therapeutics · doi:10.1097/00045391-200209000-00008 · Cited by 18
What should the optimal target hemoglobin be?11This article is dedicated to the memory of Fernando Valderrábano, who, over the last decade, was involved in the study of renal anemia with the goal of achieving optimal care and improved quality of life for all patients with CKD.
Gómez, J. M. L., & Carrera, F. (2002) · Kidney International · doi:10.1046/j.1523-1755.61.s80.8.x · Cited by 18
Pressure-overload cardiomyopathy in end-stage renal disease
London, G. M., Guérin, A. P., & Marchais, S. J. (1999) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-199903000-00005 · Cited by 18
Anaemia, cardiovascular disease and kidney disease: integrating new knowledge in 2002
Stevens, L. A., & Levin, A. (2003) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200303000-00002 · Cited by 18
Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA)
Goldsmith, D. J. A., & Covic, A. C. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq099 · Cited by 18
Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease
Jablonski, K., & Chonchol, M. (2014) · F1000Prime Reports · doi:10.12703/p6-72 · Cited by 17
Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials
Hamano, T., Yamaguchi, Y., Goto, K., Martin, S., Jiletcovici, A., Dellanna, F., Akizawa, T., & Barratt, J. (2024) · Advances in Therapy · doi:10.1007/s12325-023-02728-2 · Cited by 17
Understanding cardiac biomarkers in end‐stage kidney disease: Frequently asked questions and the promise of clinical application
Roberts, M. A., HEDLEY, A. J., & Ierino, F. L. (2010) · Nephrology · doi:10.1111/j.1440-1797.2010.01413.x · Cited by 17
Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
Hofmann, M., & Valliant (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s44944 · Cited by 17
Changes to the End-Stage Renal Disease Quality Incentive Program
Fishbane, S. N., Miller, I. J., Wagner, J. D. O., & Masani, N. N. (2012) · Kidney International · doi:10.1038/ki.2012.138 · Cited by 17
Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis
Lestz, R. M., Fivush, B. A., & Atkinson, M. A. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2820-9 · Cited by 17
Iron repletion is associated with reduction in platelet counts in non-dialysis chronic kidney disease patients independent of erythropoiesis-stimulating agent use: a retrospective cohort study
Yessayan, L., Yee, J., Zasuwa, G., Frinak, S., & Besarab, A. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-119 · Cited by 17
Self-citation
Mortality and Cardiovascular Morbidity Associated with Haemoglobin Levels: A Pooled Analysis of Randomised Controlled Trials
Locatelli, F., de Francisco, A., Deray, G., Fliser, D., Armstrong, G., Dougherty, F. C., & Ehrhard, P. B. (2014) · Nephron Clinical Practice · doi:10.1159/000366478 · Cited by 17
It's Time to Compare Anemia Management Strategies in Hemodialysis
Coyne, D. W. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02490409 · Cited by 17
Sickle Trait in African-American Hemodialysis Patients and Higher Erythropoiesis-Stimulating Agent Dose
Derebail, V. K., Lacson, E. K., Jr., Kshirsagar, A. V., Key, N. S., Hogan, S. L., Hakim, R. M., Mooney, A., Jani, C. M., Johnson, C., Hu, Y., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013060575 · Cited by 17
The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
Robles, N. R. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0378-y · Cited by 17
The Incidence and Pathophysiology of the Obesity Paradox: Should Peritoneal Dialysis and Kidney Transplant Be Offered to Patients with Obesity and End-Stage Renal Disease?
Vareldzis, R., Naljayan, M. V., & Reisin, E. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0882-y · Cited by 17
Comparing Therapeutic Efficacy and Safety of Epoetin Beta and Epoetin Alfa in the Treatment of Anemia in End-Stage Renal Disease Hemodialysis Patients
Azmandian, J., Abbasi, M. R., Pourfarziani, V., Nasiri, A. A., Ossareh, S., Jahromi, S. E., Sanadgol, H., Amini, S., & Farahani, A. S. (2018) · American Journal of Nephrology · doi:10.1159/000493097 · Cited by 17
Chronic Kidney Disease and End Stage Renal Disease
Martinusen, D. J., Marin, J., Cheng, E., & Lau, W. (2020) · Advanced clinical pharmacy - research, development and practical applications/Advanced clinical pharmacy - research, development and practical applications · doi:10.1007/978-3-030-37655-0_4 · Cited by 17
Evaluation of Hematocrit in Adults with Dengue by a Laboratory Information System
Sahassananda, D., Thanachartwet, V., Chonsawat, P., Wongphan, B., Chamnanchanunt, S., Surabotsophon, M., & Desakorn, V. (2021) · Journal of Tropical Medicine · doi:10.1155/2021/8852031 · Cited by 17
Association of anemia and iron parameters with mortality among prevalent peritoneal dialysis patients in Taiwan: the AIM-PD study
Kuo, K., Liu, J., Lin, M., Hsu, C., Tarng, D., Hung, S., Kuo, K., Liu, J., Hsu, C., Lin, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-05200-3 · Cited by 17
Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
Fujikawa, R., Nagao, Y., Fujioka, M., & Akizawa, T. (2022) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13820 · Cited by 17
The anaemia control model: Does it help nephrologists in therapeutic decision-making in the management of anaemia?
Bucalo, M. L., Barbieri, C., Roca, S., Titapiccolo, J. I., Romero, M. S. R., Ramos, R., Pérez, M. A., Manzano, D., Mari, F., & Molina, M. (2018) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2018.10.001 · Cited by 17
Management of Cardiovascular Diseases in Chronic Hemodialysis Patients
Zhang, Z., & Wang, Y. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2407185 · Cited by 17
The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors
Locatelli, F., Vecchio, L. D., & Elliott, S. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad105 · Cited by 17
Cerebral oximetry values in dialyzed surgical patients: a comparison between hemodialysis and peritoneal dialysis
Papadopoulos, G., Dounousi, E. C., Papathanasiou, A. I., Παπαθανάκος, Γ., & Tzimas, P. G. (2013) · Renal Failure · doi:10.3109/0886022x.2013.794675 · Cited by 17
Clinical Characteristics and Survival in End-Stage Renal Disease Patients with Arteriosclerosis obliterans
Nakamura, S., Sasaki, O., Nakahama, H., Inenaga, T., & Kawano, Y. (2002) · American Journal of Nephrology · doi:10.1159/000065267 · Cited by 17
Triumph and tragedy: anemia management in chronic kidney disease
Novak, J. E., & Szczech, L. A. M. (2008) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32830c488d · Cited by 17
Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma!
Lapchak, P. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.517954 · Cited by 17
Recombinant human epoetin beta in the treatment of renal anemia
Vecchio, L. D., Cavalli, A., Pozzoni, P., & Locatelli, F. (2008) · Therapy · doi:10.2217/14750708.5.1.91 · Cited by 17
Cardiorenal Anemia Syndrome in Chronic Kidney Disease
Tarng, D. (2007) · Journal of the Chinese Medical Association · doi:10.1016/s1726-4901(08)70031-5 · Cited by 17
Hemoglobin Kinetics and Long-term Prognosis in Heart Failure
Díez‐López, C., Lupón, J., de Antonio, M., Zamora, E., Domingo, M., Santesmases, J., Troya, M. I., Boldo, M., & Bayés‐Genís, A. (2016) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.02.028 · Cited by 17
Treatment of Anemia in Heart Failure
Jelani, Q., & Katz, S. D. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181e71150 · Cited by 17
Should the Hematocrit (Hemoglobin) Be Normalized in Pre-ESRD or Dialysis Patients? Yes!
Besarab, A., & Aslam, M. A. (2000) · Blood Purification · doi:10.1159/000046935 · Cited by 17
Self-citation
Normalization of haemoglobin concentration with recombinant erythropoietin has minimal effect on blood haemostasis
Christensson, A. G., Danielson, B. G., & Lethagen, S. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.2.313 · Cited by 17
Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer
Westin, S. N., Skinner, E. N., Funk, M. J., Gehrig, P., & Le, L. V. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.12.026 · Cited by 17

Authors: Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
Affiliations: Henry Ford Hospital (US)
University of Virginia Health System (US)
Amgen (United States) (US)
University of California, Los Angeles (US)
Duke University (US)
ORCID: Bolton, W. Kline
Goodkin, David A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1998-08-27
Volume: 339
Issue: 9
Pages: 584-590
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199808273390903
OpenAlex: W2331665138
Cited by: 1,930
References: 28
Citations by year: 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
FWCI: 21.09
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
Health Sciences › Medicine › Hematology › Blood transfusion and management
Keywords: hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks